SCHEMBL2652860

SCHEMBL2652860

O=CC(=O)c1cccc(Cl)c1C(=O)C=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
TSHR P16473 1/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
PBRM1 Q86U86 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 2/20 0.41
FEN1 P39748 2/20 0.40
MAPK1 P28482 1/20 0.40
NPC1 O15118 1/20 0.39
GLA P06280 1/20 0.39
RAB9A P51151 1/20 0.39
ERCC5 P28715 1/20 0.37
JAK2 O60674 1/20 0.37
CYP3A4 P08684 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3125268 0.89 ALDH1A1 (0.56) ALDH1A1TSHRCES2CES1MEN1
SCHEMBL11702408 0.87 ALDH1A1 (0.46) ALDH1A1TSHRCES2CES1TDP1
Water SCHEMBL11418867 0.85 ALDH1A1 (0.44) ALDH1A1TSHRCES2CES1TDP1
SCHEMBL8723935 0.83 TSHR (0.61) ALDH1A1TSHRCES2CES1MEN1
SCHEMBL293634 0.83 CES2 (0.60) ALDH1A1TSHRCES2CES1KMT2A
SCHEMBL29952517 0.83 CES2 (0.60) ALDH1A1TSHRCES2CES1KMT2A
Water SCHEMBL10353121 0.81 CES2 (0.58) ALDH1A1TSHRCES2CES1KMT2A
SCHEMBL2865994 0.80 CYP1A2 (0.50) ALDH1A1TSHRCES2CES1PBRM1
SCHEMBL2650858 0.78 CES2 (0.50) ALDH1A1TSHRCES2CES1MEN1
SCHEMBL2651206 0.75 ALDH1A1 (0.36) ALDH1A1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349856-B1 ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 EP disclosed
EP-1349856-A2 ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2003-10-08 EP disclosed
US-6482951-B2 ISOINDOLIN-1-ONE-SUBSTITUTED PROPIONAMIDE GLUCOKINASE ACTIVATORS WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES HOFFMANN-LA ROCHE INC. 2002-11-19 US disclosed
US-20020082260-A1 Isoindolin-1-one glucokinase activators GUERTIN KEVIN RICHARD (US) 2002-06-27 US disclosed
WO-2002048106-A2 ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA-ROCHE AG (CH) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082260-A1 Isoindolin-1-one glucokinase activators GCKR, GCK, PGK2 ALDH1A1 1838/4885TSHR 3783/4885CES2 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.